Abstract
Abnormal interactions of Zn2+ and Cu2+ with the amyloid β-peptide (Aβ) are proposed to play an important role in the neuropathogenesis of Alzheimer’s disease (AD). Metal chelators are potential therapeutic agents for AD because they could sequester metals ions from Aβ aggregates and reverse the aggregation. In this study, two nitrogencontaining ligands, TACN and BPA, have been investigated as possible metal chelators in the therapy of Alzheimer’s disease. The interactions between the chelators and Aβ40 aggregates are studied by turbidometry, thioflavin T (ThT) fluorescence spectroscopy, inductively coupled plasma mass spectrometry (ICP-MS), BCA protein assay, circular dichroism spectroscopy (CD), and atomic force microscopy (AFM). The results demonstrates that TACN and BPA are capable of both disrupting and preventing Zn2+ or Cu2+-induced Aβ40 aggregation. Moreover, they can also suppress the production of H2O2 induced by Cu-Aβ40, associated with toxic oxidative stress in AD.
Keywords: Alzheimer’s disease, Amyloid β-peptide, Metal, Chelators.
CNS & Neurological Disorders - Drug Targets
Title:Two Nitrogen-containing Ligands as Inhibitors of Metal-Induced Amyloid β-Peptide Aggregation
Volume: 13 Issue: 1
Author(s): Tingting Chen, Shajun Zhu, Siyuan Liu, Yapeng Lu and Li Zhu
Affiliation:
Keywords: Alzheimer’s disease, Amyloid β-peptide, Metal, Chelators.
Abstract: Abnormal interactions of Zn2+ and Cu2+ with the amyloid β-peptide (Aβ) are proposed to play an important role in the neuropathogenesis of Alzheimer’s disease (AD). Metal chelators are potential therapeutic agents for AD because they could sequester metals ions from Aβ aggregates and reverse the aggregation. In this study, two nitrogencontaining ligands, TACN and BPA, have been investigated as possible metal chelators in the therapy of Alzheimer’s disease. The interactions between the chelators and Aβ40 aggregates are studied by turbidometry, thioflavin T (ThT) fluorescence spectroscopy, inductively coupled plasma mass spectrometry (ICP-MS), BCA protein assay, circular dichroism spectroscopy (CD), and atomic force microscopy (AFM). The results demonstrates that TACN and BPA are capable of both disrupting and preventing Zn2+ or Cu2+-induced Aβ40 aggregation. Moreover, they can also suppress the production of H2O2 induced by Cu-Aβ40, associated with toxic oxidative stress in AD.
Export Options
About this article
Cite this article as:
Chen Tingting, Zhu Shajun, Liu Siyuan, Lu Yapeng and Zhu Li, Two Nitrogen-containing Ligands as Inhibitors of Metal-Induced Amyloid β-Peptide Aggregation, CNS & Neurological Disorders - Drug Targets 2014; 13 (1) . https://dx.doi.org/10.2174/18715273113129990076
DOI https://dx.doi.org/10.2174/18715273113129990076 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Drug Repurposing: Promises of Edaravone Target Drug in Traumatic Brain Injury
Current Medicinal Chemistry Liposomes as siRNA Delivery Vectors
Current Drug Metabolism <i>In-silico</i> Prediction of the Beta-carboline Alkaloids Harmine and Harmaline as Potent Drug Candidates for the Treatment of Parkinson’s disease
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Effects of Erythropoietin on Brain Function
Current Pharmaceutical Biotechnology Synthesis of Novel 4-(Dimethylaminoalkyl)piperazine-1-carbodithioa t e Derivatives as Cholinesterase Inhibitors
Letters in Drug Design & Discovery A Perspective on Monoamine Oxidase Enzyme as Drug Target: Challenges and Opportunities
Current Drug Targets Cannabinoid Drugs and Enhancement of Endocannabinoid Responses: Strategies for a Wide Array of Disease States
Current Molecular Medicine Astrocyte Pathology in Major Depressive Disorder: Insights from Human Postmortem Brain Tissue
Current Drug Targets Using Mass Spectrometry-Based Peptidomics to understand the Brain and Disorders such as Parkinson’s Disease and Schizophrenia
Current Topics in Medicinal Chemistry Sub-Chronic Exposure of Non-Observable Adverse Effect Dose of Terbufos Sulfone: Neuroinflammation in Diabetic and Non-Diabetic Rats
CNS & Neurological Disorders - Drug Targets Amyloidogenesis of Natively Unfolded Proteins
Current Alzheimer Research Neurogenesis in Alzheimers Disease: A Realistic Alternative to Neuronal Degeneration?
Current Signal Transduction Therapy Evaluation of the Binding Affinity of a Gonadotropin-Releasing Hormone Analogue (GnRH-a) Buserelin through <i>In silico</i> and <i>In vivo</i> Testing in <i>Clarias magur</i>
Current Proteomics The gp130 Receptor Cytokine Family: Regulators of Adipocyte Development and Function
Current Pharmaceutical Design ABC Subfamily D Proteins and Very Long Chain Fatty Acid Metabolism as Novel Targets in Adrenoleukodystrophy
Current Drug Targets Proteasomes as Drug Targets
Current Drug Targets The Regulatory Effects of Glutamine on Illness and Health
Protein & Peptide Letters Editorial [Hot topic: Role of Inflammation in Neurological and Psychiatric Disorders (Guest Editor: Mohtashem Samsam)]
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Curcumin Activates the Nrf2 Pathway and Induces Cellular Protection Against Oxidative Injury
Current Molecular Medicine Influence of Lithium Treatment on GDNF Serum and CSF Concentrations in Patients with Early Alzheimers Disease
Current Alzheimer Research